Biocon Ltd. NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

349.15 -3.35 (-0.95%)

561.2K

NSE+BSE Volume

NSE 10 Oct, 2025 10:33 AM (IST)

US FDA Approval

Biocon's arm gets US FDA nod for its ANDA for Rifaximin tablets, with a $1.8 billion market size See details

Biocon Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Biocon Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 5
Author: Axis Direct

Keep track of all breaking news and updates on Biocon Ltd. from all sources in a single place.

Load latest

Is Biocon Ltd. worth buying?

728 Votes:

Buy 75.0%

Sell 16.35%

Hold 8.65%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf